- Home
- / Mycenax Biotech
Mycenax Biotech
Stock Price
NT$50.2
2024-10-29
Market Capitalization
NT$10.3 B
2024-10-29
Revenue
NT$740.2 M
FY, 2025
Mycenax Biotech Summary
Company Summary
- Overview
- Mycenax Biotech (永昕生物醫藥股份有限公司) is a company that provides biopharmaceutical development services. It specializes in cell line development activities from vector construction to generating cell banks for GMP manufacturing. In addition, the company supports early-stage material generation for proof-of-concept studies or preclinical development programs.
- Type
- Public
- Status
- Active
- Founded
- 2001
- HQ
- Zhunan, TW | view all locations
- Website
- https://www.mycenax.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Chih-Yung Lin, VP & Head of GMP Operation Center
Chia-Ling Lin, Director
Wei-I Chou, Head of Pharmaceutical Development
Operating MetricsView all
Enterprise Customers
80
Sep, 2023
Projects
150
Sep, 2023
Manufacturing Facilities
2
Sep, 2023
LocationsView all
3 locations detected
Zhunan HQ
Taiwan
4F, No. 50-7, Keyan Road
Taipei, Taipei City
Taiwan
16F-3, Building F, No. 3, Yuan-Qu Street, Nan-Kang District
Zhunan
Taiwan
3F, No. 8, Kedung 3 Road
Mycenax Biotech Financials
Summary Financials
- Revenue (FY, 2025)
- NT$740.2M
- Gross profit (FY, 2025)
- NT$114.2M
- Net income (FY, 2025)
- (NT$448.6M)
- Cash (FY, 2025)
- NT$224.5M
- EBIT (FY, 2025)
- (NT$415.1M)
- Enterprise value
- $11.2B